Fineline Cube

Follow:
14486 Articles
Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India
CompanyDeals

Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India

Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC
CompanyDrug

Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC

Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
CompanyDrug

Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs
Policy / Regulatory

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs

GSK Secures FDA Approval for Blenrep in Multiple Myeloma
CompanyDrug

GSK Secures FDA Approval for Blenrep in Multiple Myeloma

Pfizer R&D & ATLATL Forge Open Innovation Partnership in Beijing
CompanyDeals

Pfizer R&D & ATLATL Forge Open Innovation Partnership in Beijing

RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
CompanyDrug

RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)
CompanyDrug

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
CompanyDrug

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
CompanyDrug

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC
CompanyDrug

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC